Data gathered: May 17
Alternative Data for Agenus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 10 | Sign up | Sign up | Sign up |
| Sentiment | 78 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 31 | Sign up | Sign up | Sign up |
| Patents | 89 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 21 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,458 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,681 | Sign up | Sign up | Sign up |
| Twitter Mentions | 60 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 24 | Sign up | Sign up | Sign up |
| Linkedin Employees | 297 | Sign up | Sign up | Sign up |
About Agenus
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer.
| Price | $10.50 |
| Target Price | Sign up |
| Volume | 405,010 |
| Market Cap | $226M |
| Year Range | $4.97 - $26.2 |
| Dividend Yield | 0% |
| PE Ratio | 0.93 |
| Revenue per Employee | $302,657 |
| Industry | Biotechnology |
In the news
 |
Agenus sets FDA meeting for cancer therapy pathMay 16 - Investing.com |
 |
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal CancerMay 16 - Marketscreener.com |
 |
B. Riley Weighs in on Agenus Inc.’s Q2 2024 Earnings (NASDAQ:AGEN)May 14 - ETF Daily News |
|
Agenus Inc. Forecasted to Earn Q2 2024 Earnings of ($3.10) Per Share (NASDAQ:AGEN)May 10 - ETF Daily News |
|
William Blair Equities Analysts Boost Earnings Estimates for Agenus Inc. (NASDAQ:AGEN)May 10 - ETF Daily News |
Buy Rating for Agenus Inc. on Strong Financial Position and Promising Clinical MilestonesMay 9 - TipRanks |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '24 | 28M | 110,000 | 28M | -62M | -30M | -3.040 |
| Q4 '23 | 84M | 260,000 | 83M | -46M | 1M | -0.130 |
| Q3 '23 | 24M | 300,000 | 24M | -62M | -43M | -0.160 |
| Q2 '23 | 25M | 250,000 | 25M | -69M | -52M | -0.200 |
| Q1 '23 | 23M | 2.3M | 21M | -68M | -52M | -0.220 |
Insider Transactions View All
| ARMEN GARO H filed to buy 625,969 shares at $0.6. February 15 '24 |
| WIINBERG ULF filed to buy 124,063 shares at $0.8. November 17 '23 |
| O'Day Steven J filed to sell 61,321 shares at $3.1. January 6 '22 |
Similar companies
Read more about Agenus (AGEN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Agenus?
The Market Cap of Agenus is $226M.
What is Agenus' PE Ratio?
As of today, Agenus' PE (Price to Earnings) ratio is 0.93.
How Many People Work at Agenus?
As of our latest update, Agenus employed approximately 533 people worldwide. However, it's important to note that Agenus' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.
What is Agenus' revenue per employee?
$302,657. To calculate Agenus' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.
What is the current stock price of Agenus?
Currently, the price of one share of Agenus stock is $10.50.
How can I analyze the AGEN stock price chart for investment decisions?
The AGEN stock price chart above provides a comprehensive visual representation of Agenus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Agenus shares. Our platform offers an up-to-date AGEN stock price chart, along with technical data analysis and alternative data insights.
Does AGEN offer dividends to its shareholders?
As of our latest update, Agenus (AGEN) does not offer dividends to its shareholders. Investors interested in Agenus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Agenus?
Some of the similar stocks of Agenus are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.